Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children

Alessandra Viganò, Grace M. Aldrovandi, Vania Giacomet, Marzia Merlo, Laura Martelli, Silvia Beretta, Paola Luraschi, Giuseppe Rombolà, Stefano Mora

Research output: Contribution to journalArticle

Abstract

Objective: To assess the impact on immunological, virological and metabolic parameters of replacing protease inhibitors (PIs) with efavirenz and replacing stavudine with tenofovir in HIV-infected children. Methods: A 48-week prospective evaluation of 28 HIV-infected children, with stable undetectable HIV-1 loads, who were taking highly active antiretroviral therapy (HAART) containing lamivudine, stavudine and a PI. Individuals were randomized to switch PI to efavirenz and stavudine to tenofovir at baseline (Group 1) or at week 24 (Group 2). Patient assessment included: clinical evaluation, viral load, CD4+ T-cell count, fasting blood levels and urine samples. Results: All individuals maintained HIV RNA + T-cell count through week 48. In Group 1 individuals, a significant decrease in cholesterol (P

Original languageEnglish
Pages (from-to)917-924
Number of pages8
JournalAntiviral Therapy
Volume10
Issue number8
Publication statusPublished - 2005

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children'. Together they form a unique fingerprint.

Cite this